Citadel Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Citadel Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-9,200	Closed	-$897K	–	9428
2015 Q1	$897K	Buy	9,200 +5,800	+171%	+$614K	﹤0.01%	4071
2014 Q4	$315K	Sell	3,400 -2,600	-43%	-$205K	﹤0.01%	5360
2014 Q3	$413K	Sell	6,000 -20,100	-77%	-$1.44M	﹤0.01%	4872
2014 Q2	$2.73M	Sell	26,100 -15,500	-37%	-$1.32M	﹤0.01%	2441
2014 Q1	$3.45M	Buy	41,600 +40,200	+2,871%	+$3.72M	﹤0.01%	2098
2013 Q4	$91K	Buy	+1,400	New	+$83.1K	﹤0.01%	5686

Citadel Advisors's GEVA Position: Q1 2015 in Review

Citadel Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 11,940 shares — an estimated $1.26M sold.

Citadel Advisors first reported a position in GEVA in Q4 2013 and held it in 5 quarters. The position peaked at $2.58M in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Citadel Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Citadel Advisors sold 11,940 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $1.26M.
Citadel Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 5 quarters.
Citadel Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.58M in Q1 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Citadel Advisors's 13F filing for Q1 2015, filed 15 May 2015.